Abstract
SELECTION, a randomized, double-blind, placebo-controlled phase 2b/3 trial (NCT02914522), evaluated filgotinib (FIL; JAK1 preferential inhibitor) in moderately to severely active ulcerative colitis. We assessed FIL’s effects on EQ-5D-5L utility and Work Productivity and Activity Impairment (WPAI) scores during the SELECTION study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
